Bally’s Corporation (NYSE: BALY) eyes evoke plc (LSE: EVOK): why a William Hill deal would reshape UK gambling
Read More Pharma Industry News Travere Therapeutics stock soars 25% as FDA skips advisory panel for FSGS drug FILSPARI Travere stock jumped 25% after the FDA waived an advisory panel for its FSGS drug. Find out why FILSPARI could transform the rare kidney disease market. byPallavi MadhirajuSeptember 10, 2025